US Drug Recall Register
Class II · Moderate risk Terminated Initiated Oct 3, 2016 (10 years ago)

PredniSONE Tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.

What was recalled

PredniSONE Tablets USP, 1 mg, 100-count bottles, Rx only, Distr. by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-4741-25.

Recalling firm
West-Ward Pharmaceutical
NDC code
0054-4741-25
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0008-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Prednisone recalls

See all
Class II · Moderate risk Terminated

Prednisone Tablets USP

Reason Presence of foreign tablet: 2.5 mg tablet in a 20 mg bottle of Prednisone Tablets

Strides Pharma Inc. NDC 64380-785-06 D-1330-2022
Class II · Moderate risk Terminated

PredniSONE Tablets

Reason CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cardinal Healthcare D-0193-2024
Class II · Moderate risk Terminated

Prednisone Tablets

Reason Labeling: Label Mix Up: bottle labeled to contain Prednisone Tablets, USP 2.5 mg actually contained Prednisone Tablets, USP 10 mg

Lannett Company, Inc. NDC 0527-2931-37 D-1508-2020
Class III · Low risk Terminated

Prednisone 20 mg

Reason Labeling: Not elsewhere classified. NDC number is incorrect on the container.

Northwind Pharmaceuticals LLC NDC 51655-320-53 D-0485-2016
Class II · Moderate risk Terminated

Prednisone active pharmaceutical ingredient packaged in varying…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-858-2015